Compare INDV & HLNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | INDV | HLNE |
|---|---|---|
| Founded | N/A | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 3.9B |
| IPO Year | 2014 | 2017 |
| Metric | INDV | HLNE |
|---|---|---|
| Price | $40.48 | $84.28 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $156.78 |
| AVG Volume (30 Days) | ★ 1.6M | 906.1K |
| Earning Date | 06-08-2026 | 05-21-2026 |
| Dividend Yield | N/A | ★ 2.44% |
| EPS Growth | ★ 8100.00 | 41.64 |
| EPS | 0.69 | ★ 3.98 |
| Revenue | ★ $1,239,000,000.00 | $758,993,000.00 |
| Revenue This Year | N/A | $9.69 |
| Revenue Next Year | N/A | $15.81 |
| P/E Ratio | $56.70 | ★ $21.26 |
| Revenue Growth | 4.29 | ★ 6.46 |
| 52 Week Low | $16.14 | $71.88 |
| 52 Week High | $42.81 | $161.13 |
| Indicator | INDV | HLNE |
|---|---|---|
| Relative Strength Index (RSI) | 52.62 | 54.84 |
| Support Level | $39.20 | $76.36 |
| Resistance Level | $41.00 | $88.05 |
| Average True Range (ATR) | 1.48 | 3.15 |
| MACD | -0.23 | 0.87 |
| Stochastic Oscillator | 47.74 | 66.16 |
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).
Hamilton Lane Inc is a private markets investment firm globally, providing solutions to institutional and private wealth investors around the world. Dedicated exclusively to private markets investing for more than 30 years, the firm currently employs approximately 750 professionals operating in offices throughout North America, Europe, Asia Pacific, and the Middle East. It has approximately $986 billion in assets under management and supervision, composed of nearly $141 billion in discretionary assets and more than $845 billion in non-discretionary assets. The group specializes in building flexible investment programs that provide clients access to the full spectrum of private markets strategies, sectors, and geographies.